SALT LAKE CITY, Oct. 12, 2012 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim ®, the Nrf2 Synergizer ®, today announced Darlene R. Walley, Ph.D. will serve as the Company's new Chief Science Officer.
Dr. Walley will directly oversee the expansion of the Company's research and development as it seeks to expand its offering of scientifically validated research-backed products. Prior to joining LifeVantage, Dr. Walley was founder and president of DRW Consulting, a firm specializing in assisting large and small companies in bringing new products to market. Her clients spanned the nutraceutical, pharmaceutical and biotechnology industries. In addition, Dr. Walley has led research and development teams at Procter & Gamble, as Senior Director of Research and Development at Church & Dwight, and as Vice President of Research and Development at Gillette. Dr. Walley has a Ph.D. in Chemistry from the University of Cincinnati and a B.A. in Chemistry from Case Western Reserve.
In connection with Dr. Walley's appointment, the Company also announced today that Dr. Joe McCord will continue to work with the Company to champion third-party peer reviewed studies of the Company's flagship product Protandim and to educate the increasing number of independent distributors on the advancement of Nrf2 science. Dr. McCord will remain a key member of the Company's Scientific Advisory Board, which will be led by Dr. Walley."We are excited to have Darlene leading our research and development team and believe her strong background in bringing products to market combined with our leading position in Nrf2 science will enable us to expand our healthy living product offerings," said Douglas C. Robinson, President and CEO. "We want to thank Dr. McCord for his leadership as our Chief Science Officer and his enduring legacy with Protandim and are grateful that he will continue to champion Protandim in the scientific community as well as with our independent distributors on our behalf."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts